prime-hcc: ipilimumab and nivolumab in liver cancer
Published 3 years ago • 597 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
2:04
benefits and risks of reinduction ipilimumab/nivolumab in patients with melanoma
-
1:57
recent immunotherapy advances in hcc management
-
2:08
nivolumab with ipilimumab for mrcc
-
6:16
treatment-free survival results of nivolumab and salvage nivolumab ipilimumab for accrcc
-
2:54
combining nivolumab and ipilimumab in patients with resected stage iv melanoma
-
1:43
nivolumab, ipilimumab and panitumumab in mcrc
-
8:26
front-line therapy with nivolumab and salvage nivolumab ipilimumab in patients with advanced rcc
-
1:55
neoadjuvant ipilimumab plus nivolumab in stage iii melanoma
-
3:15
icon: chemotherapy combined with ipilimumab and nivolumab in metastatic hr breast cancer
-
2:14
immuned: adjuvant nivolumab and ipilimumab increases os in stage iv melanoma
-
5:41
second-line nivolumab in liver cancer
-
3:10
advancements in immunotherapy for hepatocellular carcinoma
-
2:53
a patient with hepatocellular carcinoma (hcc) treated with nivolumab (opdivo) post sorafenib
-
5:57
considerations for using nivolumab in advanced hcc
-
1:10
dr. welling on the efficacy of nivolumab in hcc
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
5:40
nivolumab shows highly promising activity in advanced liver cancer in early-stage trial
-
6:21
new long-term data 'clearly favor' combination ipilimumab/nivolumab in melanoma
-
1:21
unmet needs in immunotherapy for hepatocellular carcinoma